Prestige Consumer Healthcare (PBH) Stock: Buy, Sell, or Hold?
$44.17
-0.80 (-1.78%)
▼
5d:
-17.1%
30d:
-8.93%
90d:
-13.93%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (80%)
Quality Score
47/100
Position
OVERSOLD
30-Day Fair Range
$45.60 – $50.03
Position: OVERSOLD
Forward P/E & Valuation
9.2x
CHEAP
vs 11.5x historical avg
Wall Street Target
$66.20
+49.9% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$41.77 / $53.40
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
⏸️ WAIT FOR STABILIZATION: PBH is down 17.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Get Alerted When PBH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$69.45
Based on 4.8% avg growth
INTRINSIC VALUE TODAY
$43.12
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PBH is currently trading at $44.17, which is considered oversold relative to its 30-day fair value range of $45.60 to $50.03. From a valuation perspective, the stock is trading at a discount (Forward PE: 9.2) compared to its historical average (11.5). Remarkably, the market is currently pricing in an annual earnings decline of 7.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, PBH is in a downtrend. Immediate support is located at $41.77, while resistance sits at $53.40.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $66.20 (+49.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PBH is in a downtrend. Immediate support is located at $41.77, while resistance sits at $53.40.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $66.20 (+49.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$45.60 -
$50.03
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
Trading Range & Key Levels
30-Day Trading Range
$45.60 -
$50.03
Current vs Trading Range
OVERSOLD
Support Level
$41.77
Resistance Level
$53.40
Current Trend
Downtrend
Technical data as of
Nov 11, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (43/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 49.9% below Wall St target ($66.20)
- WARNING: Composite score 47/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
9.22
Wall Street Target
$66.20
(+49.9%)
Revenue Growth (YoY)
22.7%
Earnings Growth (YoY)
-38.4%
Profit Margin
13.3%
Valuation Discount vs History
-7.0% cheaper
PE vs Historical
9.2 vs 11.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.0%
(market-implied from PE analysis)
1-Year Target
$41.08
(-7%)
2-Year Target
$38.20
(-14%)
3-Year Target
$35.53
(-20%)
3-Yr Target (if PE normalizes)
(PE: 9→12)
$44.30
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 5.5%)
$111.61
(+153%)
Base:
(SPY PE: 9.2, Growth: 5.5%)
$51.84
(+17%)
Bear:
(PE: 7.8, Growth: 5.5%)
$44.06
(0%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 13.88 | Current EPS (TTM): $3.24
Bull Case
$73.11
(+66%)
Analyst growth 47.8%, PE expands to 15.3
Base Case
$66.47
(+51%)
Market implied 47.8%, PE stable at 13.9
Bear Case
$30.58
(-31%)
Severe decline -20.0%, PE contracts to 11.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.2 to 11.5
Stabilization Target:
$55.07
(+24.7%)
PE Expansion Potential:
+24.7%
Share PBH Analysis
Share this live PBH analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.
Last updated: November 11, 2026 7:30 PM ET
Data refreshes hourly during market hours. Next update: 8:30 PM
Data refreshes hourly during market hours. Next update: 8:30 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PBH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$208 | 23 SELL |
|
ALKS
Alkermes Plc |
STRONG BUY
20 analysts |
$58 | 33 SELL |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$687 | 52 HOLD |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$63 | 53 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive PBH Research Pages
